A New Treatment to Reduce Scarring
Award amount
$306,161Program and phase
SBIR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Kalyra Pharmaceuticals, Inc.
- Proposal award date
- 2016-05-15
- Contract end date
- 2017-11-14
- UEI
- JW3AWK3ATUE9
- Solicitation number
- PA14-071
- Topic code
- 300
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A New Class of Non-Opioid Analgesics for Use in Chronic Pain Management
- Novel MAP Kinase Pathway Inhibitors to Treat Pancreatic Ductal AdenoCarcinoma
- A new class of non opioid analgesics for use in chronic pain management
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- A platform for T-cell receptor mimic antibody generation modeled using pHLA-A*11:01 KRAS G12D
- Combinatorial pipeline for discovery of anti-GPCR Nanobodies
- Development of a GBP-based glycosylation analysis system
- Extended-release injectable gel for multi-day treatment of postoperative pain
- eMOA: A Multi-Omic Service for Mechanism of Action Determination in Drug Screening
Research funding history
4 SBIR/STTR records share this UEI (2015–2017). Reported award amounts total $4,073,230. Reported amounts are not federal obligations.
Phases: Phase I, Phase II, Phase II – Direct to Phase II
Agencies: Department of Health and Human Services, Department of Defense